OBJECTIVE: This study was performed to investigate serum prolidase enzyme activity and oxidative stress in patients diagnosed with fibromyalgia (FM). METHODS: The study population consisted of 40 patients with a previous diagnosis of FM and 30 healthy subjects. We measured serum prolidase enzyme activity, total antioxidant status (TAS), total oxidative status (TOS), oxidative stress index (OSI), and paraoxonase-1 (PON-1) levels. RESULTS: On average, FM patients were diagnosed within 3.2 years of symptom onset, and patients had a mean of 14 tender points. There were no significant differences between patients and controls in age, body mass index, serum TAS, or PON-1 levels. However, patients with FM demonstrated higher serum prolidase activity, TOS, and OSI than the control group. Serum prolidase activity was positively correlated with serum TOS, OSI, and visual analog scale pain and fatigue scores. No correlation was found between serum prolidase activity and FM duration or the average number of tender points. DISCUSSION: Our results demonstrate a previously unreported association between serum prolidase enzyme activity and FM. Increased prolidase activity may contribute to the pathogenesis of FM, and measuring serum prolidase enzyme activity may be a useful FM biomarker.
OBJECTIVE: This study was performed to investigate serum prolidase enzyme activity and oxidative stress in patients diagnosed with fibromyalgia (FM). METHODS: The study population consisted of 40 patients with a previous diagnosis of FM and 30 healthy subjects. We measured serum prolidase enzyme activity, total antioxidant status (TAS), total oxidative status (TOS), oxidative stress index (OSI), and paraoxonase-1 (PON-1) levels. RESULTS: On average, FM patients were diagnosed within 3.2 years of symptom onset, and patients had a mean of 14 tender points. There were no significant differences between patients and controls in age, body mass index, serum TAS, or PON-1 levels. However, patients with FM demonstrated higher serum prolidase activity, TOS, and OSI than the control group. Serum prolidase activity was positively correlated with serum TOS, OSI, and visual analog scale pain and fatigue scores. No correlation was found between serum prolidase activity and FM duration or the average number of tender points. DISCUSSION: Our results demonstrate a previously unreported association between serum prolidase enzyme activity and FM. Increased prolidase activity may contribute to the pathogenesis of FM, and measuring serum prolidase enzyme activity may be a useful FM biomarker.
Authors: Mario D Cordero; Eduardo Díaz-Parrado; Angel M Carrión; Simona Alfonsi; José Antonio Sánchez-Alcazar; Pedro Bullón; Maurizio Battino; Manuel de Miguel Journal: Antioxid Redox Signal Date: 2012-11-16 Impact factor: 8.401
Authors: Jaime C Branco; Bernard Bannwarth; Inmaculada Failde; Jordi Abello Carbonell; Francis Blotman; Michael Spaeth; Fernando Saraiva; Francesca Nacci; Eric Thomas; Jean-Paul Caubère; Katell Le Lay; Charles Taieb; Marco Matucci-Cerinic Journal: Semin Arthritis Rheum Date: 2009-02-27 Impact factor: 5.532
Authors: Mario D Cordero; Elísabet Alcocer-Gómez; Francisco J Cano-García; Manuel De Miguel; Angel M Carrión; Plácido Navas; José A Sánchez Alcázar Journal: PLoS One Date: 2011-10-28 Impact factor: 3.240
Authors: Theoharis C Theoharides; Irene Tsilioni; Lauren Arbetman; Smaro Panagiotidou; Julia M Stewart; Rae M Gleason; Irwin J Russell Journal: J Pharmacol Exp Ther Date: 2015-08-25 Impact factor: 4.030
Authors: Jorge A Ramírez-Tejero; Esther Martínez-Lara; M Ángeles Peinado; María Luisa Del Moral; Eva Siles Journal: Nutrients Date: 2020-08-09 Impact factor: 5.717